The predictive value of C-reactive protein on recurrence of atrial fibrillation after cardioversion with or without treatment with atorvastatin
Niklas Höglund(Umeå University), Kurt Boman(Umeå University), Steen M. Jensen(Umeå University), Jonas Andersson(Skellefteå Hospital), Mårten Rosenqvist(Stockholm South General Hospital), Per Tornvall(Karolinska Institutet), Henrik Almroth(Örebro University Hospital), Anders Englund(Gentofte Hospital)
Cited by 5
Related Papers
SCORE2 risk prediction algorithms: new models to estimate 10-year risk of cardiovascular disease in Europe
|European Heart Journal|2021|1.7k
Intensive Lipid Lowering with Simvastatin and Ezetimibe in Aortic Stenosis
|New England Journal of Medicine|2008|1.6k
Outcomes 1 Year after Thrombus Aspiration for Myocardial Infarction
|New England Journal of Medicine|2014|395
Bivalirudin versus Heparin Monotherapy in Myocardial Infarction
|New England Journal of Medicine|2017|298
Natriuretic peptides and integrated risk assessment for cardiovascular disease: an individual-participant-data meta-analysis
|The Lancet Diabetes & Endocrinology|2016|225